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Inhibitors of Cell Migration that Inhibit
Intracellular Paxillin/4 Binding: A Well-
Documented Use of Positional Scanning Libraries
this class of integrins are under development for the
treatment of asthma and multiple sclerosis [8–13], inhibi-
tors targeting the unique cytoplasmic Paxillin/4 inter-
action have not yet been described or explored. Such
intracellular versus extracellular inhibitors offer a poten-
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The Scripps Research Institute tial opportunity for the development of compounds with
distinct therapeutic profiles, would constitute a rare ex-10550 North Torrey Pines Road
La Jolla, California 92037 ample of small molecule therapeutic intervention
through disruption of a protein-protein interaction, and
could ultimately lead to new treatments for diseases
including asthma, multiple sclerosis, and rheumatoidSummary
arthritis.
Since the structural basis of the Paxillin/4 interactionScreening combinatorial libraries for inhibition of Pax-
illin binding to the cytoplasmic tail of the integrin 4 is unknown, a combinatorial chemistry approach was
undertaken in search of small molecule antagonists ofprovided the first inhibitors of this protein-protein in-
teraction implicated in enhanced rates of cell migra- this protein-protein interaction [14, 15]. Our efforts in this
area have focused on the exploitation of a technicallytion and chronic inflammation. The preparation of sub-
structure analogs of the lead identified features nondemanding solution-phase strategy that dependa-
bly delivers pure individual compounds or small to largerequired for activity, those available for modification,
and those that may be removed. The most potent lead combinatorial mixtures [16, 17]. We recently reported a
number of such libraries [18–20], including the solution-structure was shown to inhibit 41-mediated human
Jurkat T cell migration in a dose-dependent manner, phase preparation of a 1000 membered library assem-
bled in two distinct formats: (1) a traditional library com-validating the intracellular Paxillin/4 interaction as a
useful and unique target for therapeutic intervention. posed of 100 mixtures of 10 compounds [21], and (2) a
technically less demanding positional scanning libraryMoreover, the lead structure emerged from a library
that was prepared in two formats: (1) a traditional small [22]. The synthesis of positional scanning libraries
[23–26] represents one of the most useful protocols formixture format composed of 100 mixtures of 10 com-
pounds and (2) a positional scanning library. Their par- mixture synthesis, but can only be conducted with solu-
tion-phase techniques and is not easily adapted to solid-allel testing provided the rare opportunity to critically
compare two approaches. phase synthesis. Not only is it much less time intensive
than the parallel synthesis of individual compounds or
small mixtures and technically less demanding than spa-Introduction
tially arrayed [27] or tagged split-and-mix library synthe-
sis [28–35], but it produces depository libraries for useThe integrin41 (also know as very late antigen 4 [VLA4])
is a cell surface receptor that plays an important role in in multiple screens and capable of immediate deconvo-
lution [36–44]. Thus, unlike other mixture deconvolutionembryogenesis, hematopoiesis, and the immune re-
sponse [1, 2]. It binds natural ligands including vascular protocols, positional scanning libraries can provide lead
identities in a single round of testing. Despite thesecell adhesion molecule 1 (VCAM-1) and an alternatively
spliced connecting segment (CS-1) from the extracellu- attributes, it is not clear how well such libraries may
perform in screens for inhibition of protein-protein inter-lar matrix protein fibronectin. It mediates cellular adhe-
sion and activation through a variety of cell-cell and cell- actions. Herein, we present the results of the screening
of our libraries enlisting an ELISA assay using the immo-matrix interactions that regulate leukocyte migration
into tissues during inflammatory responses and lympho- bilized 4 cytoplasmic tail and examining the inhibition
of soluble recombinant Paxillin binding that led to thecyte trafficking [3, 4]. This integrin is believed to regulate
discovery of the first class of agents that can disruptcellular functions differently from other integrins be-
4/Paxillin binding. These agents came from the librarycause the 4 cytoplasmic tail binds tightly to the signal-
that had been prepared in two formats and represents aing adaptor protein Paxillin through a short conserved
rare case for which the parallel screening of a traditionalsequence motif dominated by two residues (Glu983 and
library of 100 mixtures of 10 compounds was conductedTyr991) [5, 6]. The 4/Paxillin interaction leads to en-
alongside the related positional scanning library suchhanced rates of cell migration and reduced rates of cell
that the results could be compared [44]. Both led to thespreading, focal adhesion, and stress fiber formation
identification of the same lead compound, demonstra-(Figure 1) [7]. These biological responses to integrin-
ting the power of the positional scanning strategy. Inmediated cell adhesion contribute to leukocyte migra-
addition, structural features contributing to this inhibi-tion and changes in gene expression important in
tion were clear from the initial screening results, andchronic inflammation. While extracellular inhibitors for
the subsequent examination of key partial structures
of the initial leads define a class of potent Paxillin/44 Correspondence: boger@scripps.edu
antagonists. The potent lead structure (IC50  300 nM)5 Present address: De´partement de Biologie Cellulaire et Mole´cu-
laire, CEA Saclay, 91191 Gif sur Yvette, France. was shown to decrease 41-mediated human Jurkat T
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Figure 1. Overview of Paxillin/4 Binding-Mediated Enhancement
of Cell Migration
Paxillin binds to the 4 cytoplasmic tail of VLA-4 (41 integrin).
Dimerization of two Paxillin/VLA-4 complexes occurs through bind-
ing to VCAM-1 in the extracellular compartment and triggers a cas-
cade of events and the gene expression responsible for cell mi-
gration.
cell migration in a dose-dependent manner, validating
this new therapeutic target.
Results and Discussion
Library Composition
We recently reported the preparation of the library of
1000 compounds from which the lead emerged in a
traditional small mixture format [21]. The structure of
the library components share an identical scaffold com-
posed of three subunits (A, B, and C) linked by amide
bonds, and a basic side chain 4-(dimethylamino)butyric
acid (DMABA) linked to the A subunit (Figure 2). Using
Figure 2. General Structure of the Library, Structure of the Ten Aro-10 different aromatic amino acids (Figure 2), the library
matic Amino Acid Subunits Used in the Library, and Library Compo-was prepared by parallel synthesis of the 100 individual
sition of the Mixture and Positional Scanning Librariescompounds constituting all possible B-C combinations
followed by their coupling with the A1–A10 mixture. This
provided a 1000-member library in a format of 100 mix-
ABCz, “C-Scan”), the C position is defined with a singletures of 10 compounds (Figure 2, 11-AByCz). We also
subunit, but A and B are undefined. The C termini ofreported the solution-phase synthesis of the positional
the library compounds were capped as methyl or ethylscanning library that contained the same compounds
esters, and the N termini were acylated with 4-(dimeth-but arranged differently [22]. The positional scanning
ylamino)butyric acid (DMABA).library consists of 30 sublibraries that are divided into
three sets. Each set is defined by a fixed position of a
monomer subunit within the tripeptide. Within set 1 (Fig- Screening Results
Initially, roughly 40,000 compounds were screened inure 2, 12-AxBC, “A-Scan”), each subunit (1–10) is indi-
vidually present at position A, and a full mixture of 1–10 approximately 2000 wells (most as a mixture of 10 com-
pounds, 50 M total concentration) in an ELISA assayis present at positions B and C. In set 2 (13-AByC,
B-Scan), the B position is defined with a single subunit, using an immobilized His-tagged4 tail [45] and examin-
ing the binding inhibition of soluble recombinant Paxillinbut A and C are undefined (full mixture). In set 3 (14-
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Figure 3. Description of the High-Throughput
Screening (ELISA)
4 tail is coated onto a Ni-NTA microtiter
plate (a ), Paxillin is allowed to bind to 4 (b ),
the first antibody is added (anti-Paxillin) (c ),
the second antibody is added (HRP-conju-
gated anti-mouse) (d ), and Paxillin/4 binding
efficiency is measured by detection at 490 nm
(e ). For binding inhibition, compounds were
added during Paxillin incubation (step b ).
100% inhibition (background) was measured
from incubation with no Paxillin and no com-
pound, 0% inhibition was measured from in-
cubation with Paxillin and no compound.
[46] (Figure 3). From this screen, mixture library 11- rived from mixture 11-AB7C7 was found to be active at
this concentration. Except for the closely related 11-AByCz (50 M; data not shown) exhibited numerous
mixture hits. This library of 1000 compounds was re- A7B10C9, the leads share an identical scaffold com-
posed of two CDPI subunits (11-AxB7C7 or 11-A7B7Cz)tested at lower concentrations (5 M total compound,
0.5 M per component), and the results are reported and led to the conclusion that the CDPI2 motif is key to
Paxillin/4 binding inhibition. We also established thatas percent inhibition versus no compound in Table 1A.
Mixtures 11-AB7C6, 11-AB7C7, 11-AB7C10, and 11- none of the lead compounds exhibited their activity by
disrupting the binding of 4 to the Ni-NTA well. WeAB10C9 showed exceptional and consistent activity in
this concentration range exhibiting 80% inhibition. In measured (anti-4) the concentration of 4 integrin
bound to the plate in the presence or absence of com-nearly each case, mixture B7 and to a lesser extent C7
mixtures, exhibited the most potent inhibition, followed pound and found that none of the lead compounds de-
stabilized the bound 4.by B10 or C10 mixtures. The presence of subunits 7 or
10 (two very close structures, see Figure 2) in each At the time the initial screening was conducted, the
Boc-protected precursors [21] to the 11-AByCz libraryof the four most active mixtures suggested a specific
structure-related inhibition. Consequently, we resynthe- (1000 compounds) lacking the DMABA side chain were
also examined as identical mixtures of 10 compoundssized each individual compound of the four most potent
mixtures from the archived Boc-B7C6, Boc-B7C7, Boc- (50 and 5 M). Although none of these derivatives was
as active as the DMABA derivatives, they did displayB7C10, and Boc-B10C9 precursors using the route pre-
viously disclosed [21]. The forty individual compounds analogous trends, with B7 and C7 mixtures exhibiting
the greatest binding inhibition (data not shown). Thesewere tested at 1 M, and the results (% inhibition) are
reported in Table 1B. Impressively, every molecule de- results suggested that either the DMABA basic side
Table 1A. Inhibition (%) of Paxillin/4 Binding by Mixtures 11-AByCz (5 M Total Compound)
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10
11-AB1Cn 17 8 21 15 14 22 27 6 2 18
11-AB2Cn 6 11 12 6 23 23 32 9 7 6
11-AB3Cn 2 14 9 17 3 15 24 17 12 21
11-AB4Cn 25 6 4 21 8 8 6 15 6 13
11-AB5Cn 24 3 15 19 11 16 19 8 16 12
11-AB6Cn 19 18 14 11 3 6 9 15 11 16
11-AB7Cn 53 61 60 58 28 78 88 72 71 80
11-AB8Cn 3 0 2 5 16 5 36 0 8 14
11-AB9Cn 25 17 19 22 16 32 38 19 32 45
11-AB10Cn 21 26 24 23 12 31 16 21 75 23
Table 1B. Inhibition (%) of Paxillin/4 Binding by Deconvoluted Samples of 11-AxByCz (1 M)
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10
11-AnB7C6 31 8 29 31 47 11 74 60 60 54
11-AnB7C7 70 58 80 76 68 66 76 74 81 63
11-AnB7C10 40 4 54 54 27 29 77 59 67 54
11-AnB10C9 29 9 72 3 2 23 63 48 10 35
Table 1C. Inhibition of Paxillin/4 Binding by Deconvoluted Samples of 11-AxByCz (IC50 in M)
A1 A2 A3 A4 A5 A6 A7 A8 A9 A10
11-AnB7C6 – – – – – – 0.5 – – –
11-AnB7C7 0.6 1.4 0.4 0.4 0.5 2.2 0.3 0.7 0.4 4.8
11-AnB7C10 – – – – – – 0.4 – – –
11-AnB10C9 – – – – – – 2.2 – – –
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chain was contributing productively to the binding inhi-
bition or that an N-terminus Boc group was detrimental.
This point will be discussed in more detail below.
We further tested the thirteen individual compounds
in italics in Table 1B at a range of concentrations, and
the results are reported as IC50 in Table 1C. Compound
11-A7B7C7, containing three CDPI subunits, was the
most effective inhibitor of Paxillin/4 binding, with a IC50
of 300 nM. However, the fact that every component of
mixture 11-AB7C7 (11-A1B7C7 to 11-A10B7C7) exhib-
ited such similar activity suggests either that the A sub-
unit is unnecessary or that the binding site is able to
accommodate a wide variety of groups at position A.
We will return to this point later.
An important feature in this work rested with the paral-
lel screening of the related positional scanning library
for which every component contained in the traditional
compound library (11-AByCz) was also present, but as-
sembled such that immediate deconvolution is possible.
This library was initially screened at the 50 M total
compound concentration and, like the traditional library,
displayed numerous active mixtures. Consequently,
they were rescreened at 5, 10, and 20 M total com-
pound concentrations. Thus, scanning for the best sub-
unit at position A by screening sublibrary 12-AxBC
showed that the greatest inhibition was observed for
mixture 12-A7BC at each concentration, identifying the
CDPI subunit as the best subunit at position A (Figure
4). Using the same procedure, CDPI was also identified
as the most effective subunit at positions B and C (Figure
4). Immediate deconvolution of the results identifies the
A7B7C7 combination as a potent Paxillin/4 binding
antagonist. Thus, the same lead compound (11-
A7B7C7) was identified from the two different combina-
torial strategies. This success must be tempered by the
fact that the positional scanning library screening and
Figure 4. Inhibition of Paxillin/4 Binding by the Positional Scanningdirect deconvolution do not identify as candidate inhibi-
Libraries 12-AxBC, 13-AByC, and 14-ABCztors 11-A3B7C7, 11-A9B7C7, or 11-A7B7C6, which
Each mixture was tested in triplicate at 5, 10, and 20 M (totalwere identified from the traditional library. This is a natu-
compound), and the results are reported as percent inhibition of
ral consequence of testing larger 100-compound mix- Paxillin/4 binding.
tures and the relative insensitivity of the assay to the
contribution of any single, uniquely acting compound in
ducted on mixtures, indicating that the CDPI subunit (7)the mixture. Thus, the global observations were effec-
was more effective than the closely related benzothio-tively detected with the positional scanning library, and
phene, benzofuran, or indole subunits (8–10), with thea useful lead structure with defined properties was iden-
more closely related indole 10 typically being better thantified. However, more subtle discoveries within the li-
subunits 8 or 9 (i.e., typically: 7  10  9  8). Conse-brary were not identified. Thus, the disadvantages asso-
quently, the subsequent studies focused on 13 addi-ciated with the loss of their detection and this
tional CDPI derivatives containing one, two, or threeinformation contained within the library must be bal-
CDPI subunits. Within each series, the new analogs con-anced against the advantages of the ease of synthesis
tained either a methyl ester or a free acid at C terminalof the parent libraries and judged in light of the objec-
position, and either a dimethylaminobutyric acidtives of the library screening. As in this case, the posi-
(DMABA), a Boc, or a free amine at N terminal position.tional scanning libraries typically would be most effec-
Previously unreported analogs [47] that contain thetive for lead identification and would be less suitable
DMABA side chain were prepared using traditional Boc-for lead optimization.
deprotection (4 N HCl-dioxane) and peptide coupling
with 4-(dimethylamino)butyric acid effected by EDCI/
DMAP (DMF). Each analog was tested for Paxillin/4Further Structure-Activity Studies
Following the identification of 11-A7B7C7 by two differ- inhibition at a single concentration (1 M), and the most
active compounds were further characterized by mea-ent combinatorial strategies, the structural features con-
tributing to its properties were defined by examining key suring their IC50 for Paxillin/4 binding inhibition. The
results are summarized in Table 2. Compounds with onepartial structures (minimal structure scanning). Notably,
a first level structure-activity relationship study was CDPI subunit (15–19) or two CDPI subunits (20–23) were
not active or were only weakly active at the concentra-available from the original library screening, albeit con-
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Table 2. Inhibition of Paxillin/4 Binding by Key Substructure Analogs of 11-A7B7C7
Inhibition of Paxillin/4 binding Inhibition of Paxillin/4 binding
Compound (% at 1 M) (IC50 in M)
Boc-CDPI-OMe, 15 3 nd
H-CDPI-OMe, 16 19 nd
H-CDPI-OH, 17 11 nd
Boc-CDPI-OH, 18 6 nd
DMABA-CDPI-OMe, 19 3 nd
Boc-CDPI2-OMe, 20 13 nd
H-CDPI2-OMe, 21 14 nd
DMABA-CDPI2-OMe, 22 36 nd
H-CDPI2-OH, 23 27 nd
Boc-CDPI3-OMe, 24 25 nd
H-CDPI3-OMe, 25 73 0.3
DMABA-CDPI3-OMe, 11-A7B7C7 78 0.3
H-CDPI3-OH, 26 68 0.5
R R R R
15 Me Boc 20 Me Boc
16 Me H 21 Me H
17 H H 22 Me DMABA
18 H Boc 23 H H
19 Me DMABA
tion tested, and only DMABA-CDPI2-OMe (22) exhibited resin loaded with 4 tail protein in the absence or pres-
ence of compound 11-A7B7C7 or in the presence ofmoderate activity (36% inhibition at 1 M). Moreover,
the activity smoothly increased as one progressed compound 11-A6B6C6 that was found to be inactive for
Paxillin/4 binding inhibition in the initial assay (data notthrough the series CDPI1  CDPI2  CDPI3. Thus, al-
though the nature of the A subunit is not critical to the shown). Bound protein was collected and separated by
electrophoresis and analyzed by immunoblotting. Com-observed activity, its presence substantially potentiates
it. Retesting compound 11-A7B7C7 confirmed its activ- pound 11-A7B7C7 markedly reduced the binding of
Paxillin to the 4 tail protein (Figure 5A). In contrast,ity (IC50  300 nM), and analog 25, lacking the basic
DMABA side chain, exhibited a similar potency (25, compound 11-A6B6C6 showed no inhibitory capacity
at 25 M. Quantification of bound Paxillin showed thatIC50  300 nM), indicating that the DMABA group is not
necessary for activity. Replacing the DMABA side chain 11-A7B7C7 reduced Paxillin/4 binding to near back-
ground levels at concentrations as low as 5 M in thiswith a Boc group (Boc-CDPI3-OMe, 24) led to a substan-
tial loss of activity. This observation confirms, as sug- assay and confirmed the selectivity and effectiveness
of 11-A7B7C7 at inhibiting Paxillin/4 binding.gested earlier, that the presence of an N-terminal Boc
group is detrimental to the inhibition properties. Just as
interestingly, analog 27, lacking both the DMABA group Inhibition of Cell Migration
at the N terminus and the methyl ester at the C terminus, The functional biological activity of 11-A7B7C7 was
exhibited only a slight reduction in potency against Pax- established by examining its effects on integrin 41-illin/4 binding. This result not only indicates that the mediated cell migration in Jurkat T cells [48]. Compound
methyl ester is dispensable, but that the in vivo activity 11-A7B7C7 efficiently blocked cell migration in a dose-
of the leads against the target protein-protein interaction dependent manner (IC5010M), validating the Paxillin/will remain relatively unchanged even upon ester hydro-
4 target for therapeutic intervention. In contrast, a com-
lysis. pound that failed to inhibit the 4/Paxillin interaction,
11-A6B6C6, had no effect at concentrations up to 15
M (Figure 5B), the maximal concentration achievableAffinity Chromatography Binding Experiments
In order to confirm the effectiveness and selectivity of in 1% DMSO. 11-A7B7C7 did not cause leakage of cyto-
plasmic lactate dehydrogenase from the cells at the11-A7B7C7 at inhibiting Paxillin/4 binding, we con-
ducted a series of binding experiments using affinity concentrations up to 15M, indicating that the inhibition
of migration was not due to cytotoxicity. Furthermore,chromatography techniques [7, 45]. Recombinant GST-
Paxillin (100 nM) was allowed to bind to a Ni2	-charged at the highest possible dose (15M), inhibition appeared
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to approach a maximum at 70%, similar to the degree
of inhibition produced by mutations in 4 that disrupt
Paxillin binding.
Significance
Screening for inhibition of Paxillin binding to the integ-
rin 4 cytoplasmic tail provided the first inhibitors of
this protein-protein interaction. The lead structure
emerged from a library of 1000 compounds that was
prepared in two formats: (1) a traditional small mixture
format composed of 100 mixtures of 10 compounds,
and (2) a less traditional positional scanning library
composed of larger mixtures (100 compounds/mix-
ture). Parallel testing of both libraries led to the identifi-
cation of the same potent lead structure and provided
the opportunity to critically compare the results de-
rived from both approaches. The deconvolution of the
traditional library required resynthesis of the individual
compounds from each active mixture from archived
samples of the library precursors, while the active lead
structure was deduced directly from the positional
scanning testing results. The traditional library pro-
vided more and subtle SAR information regarding the
Paxillin/4 inhibition, whereas the positional scanning
libraries provided the lead structure with considerably
less synthetic and screening effort. Thus, both ap-
proaches served the purposes intended, subject to
their individual limitations.
Subsequent substructure analogs of 11-A7B7C7
identified structural features required for activity,
those available for modification (A subunit), and those
that may be removed (DMABA side chain) or modified
(ester) without impacting the activity. The functional
activity of 11-A7B7C7 was established with its dose-
dependent inhibition (IC50 10 M) of 41-mediated
cell migration in Jurkat T cells. Thus, complementary
to 41 antagonists that function extracellularly by in-
hibiting the binding of VCAM-1 or fibronectin, the intra-
cellular inhibition of Paxillin/4 binding also disrupts
cell migration, offering an alternative target for thera-
peutic intervention by a rare example of a small mole-
cule disruption of an intracellular protein-protein inter-
Figure 5. Affinity Chromatography and Cell Migration Assays action [15, 49–54]. Such target validation is often first
(A) Affinity chromatography binding experiment. Upper panel: re- established with monoclonal antibodies or peptide
combinant HA-tagged GST-Paxillin (100 nM) was added to Ni2	- consensus sequences derived from endogenous li-
charged resin loaded with 4 tail protein in the absence (lane a) or
gands. It is noteworthy that the Paxillin/4 target vali-presence of compound 11-A7B7C7 (lane b, 5 M; lane c, 25 M;
dation came from this exploration of small moleculelane d, 100 M) or compound 11-A6B6C6 (lane e, 25 M). Bound
libraries.protein was collected and separated by SDS-PAGE under reducing
conditions, transferred to a nitrocellulose membrane, and stained
Experimental Procedureswith HA-tag-specific antibody, 12CA5. Lower panel: bound Paxillin
was quantified by scanning densitometry of these immunoblots us-
Production and Purification of 4 Tailing the NIH Image program. Depicted is a representative result from
The design and production of recombinant cytoplasmic 4 tail havetwo experiments.
been described [45]. Briefly, polymerase chain reaction was used(B) Effect of 11-A7B7C7 on integrin 41-mediated migration of Jur-
to generate a HindIII-BamHI fragment for each wild-type or mutantkat T cells. Cell migration was assayed in a modified Boyden cham-
integrin cytoplasmic domain. Each polymerase chain reaction prod-ber assay system as previously described [48]. In this system, migra-
tion is specific to the 4 integrin, as it is completely inhibited by
function-blocking anti-4 antibodies [48]. Transwells (Costar, Corn-
ing) polycarbonate membranes containing 3.0 m pores were
coated with 5g/ml recombinant soluble VCAM-1. Membranes were of 15 ng/ml was added to the bottom chamber. Cells were allowed
blocked with 2% BSA in PBS for 30 min at room temperature. 2.0 
 to migrate for 4 hr at 37C. Cells in the bottom chamber were enumer-
105 cells in RPMI-1640 containing the indicated concentration of ated with a hemocytometer, and data are expressed as percent
the compound and a final concentration of 0.1% DMSO were added inhibition of migration. Depicted are the mean and range of duplicate
to the top chamber. SDF-1 (R&D Systems) at a final concentration determinations from one of two experiments with similar results.
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uct was ligated into the pCR vector using a TA cloning kit (In- to the bottom chamber. Cells were allowed to migrate for 4 hr at
37C. Cells in the bottom chamber were enumerated with a hemocy-vitrogen). After cDNA sequencing, each fragment was ligated into
HindIII-BamHI sites of the modified pET15b vector described before tometer.
[45]. 4 tail was expressed in BL21(DE3)pLysS cells (Novagen), iso-
lated by Ni2	-charged resins, and further purified to90% homoge- Supplemental Data
neity using a reverse-phase C18 HPLC column (Vydac). General procedures for the preparation of the 40 individual com-
pounds derived from 11-AB7C6, 11-AB7C7, 11-AB7C10, and 11-
Production and Purification of Paxillin AB10C9, characterization data for the four lead structures 11-A3B7C7,
The expression and isolation of recombinant glutathione S trans- 11-A7B7C7, 11-A9B7C7, and 11-A7B7C6, and experimental and
ferase (GST)-Paxillin have been described [48]. characterization data for 19, 21–26, and [14C]-11-A7B7C7 are pro-
vided. Please write to chembiol@cell.com for a PDF.
Immobilized Paxillin/4 Binding Assays
Paxillin/4 binding assays were performed as follows. Ni-NTA His-
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